Changes in atherosclerosis markers during tocilizumab treatment in rheumatoid arthritis: Preliminary results

Clinical and Experimental Rheumatology

Volumn 31, Issue 2, 2013, Pages 0322-0323

  Benucci, Maurizio ^a   Manfredi, M ^b   Saviola, G ^c   Sarzi Puttini, P ^d   Atzeni, F ^d  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b Ospedale S Giovanni di Dio   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; RHEUMATOID FACTOR; SERUM AMYLOID A; TOCILIZUMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR; ANTIRHEUMATIC AGENT; AUTACOID; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; ATHEROSCLEROSIS; CD4+ CD28- T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DAS28; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LETTER; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; AGED; BLOOD; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875766730     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. AVINA-ZUBIETA JA, CHOI HK, SADATSAFAVI M et al.: Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
2. KITAS GD, GABRIEL S: Cardiovascular disease in rheumatoid arthritis: state of the art and future perspective. Ann Rheum Dis 2011; 70: 8-14.
3. ABEYWARDENA MY, LEIFERT WR, WARNES KE, VARGHESE JN, HEAD R: Cardiovascular biology of IL-6. Curr Pharmac Des 2009; 15:1809-21.
4. OLDFIELD V, DILLON S, PLOSKER GL: Tocilizumab. A review of its use in the management of rheumatoid arthritis. Drugs 2009; 69; 609-32.
5. GERLI R, SCHILLACI G, GIORDANO A et al.: CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004 8; 109: 2744-8.
6. LIUZZO G, BIASUCCI LM, TROTTA G et al.: Unusual CD4/CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol 2007; 50: 1450-8.
7. GERLI R, VAUDO G, BOCCI EB, SCHILLACI G, BISTONI O, SHOENFELD Y: Different roles for anti-cyclic citrullinated peptide antibodies and CD4/ CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher, et al. [letter]. Arthritis Rheum 2009; 60: 631-2.
8. SCARSI M, ZIGLIOLI T, AIRÒ P: Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J Rheumatol. 2010; 37: 911-6.
9. KUME K, AMANO K, YAMADA S, HATTA K, OHTA H, KUWABA N: Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol 2011; 38: 2169-71.
10. PROTOGEROU AD, ZAMPELI E, FRAGIADAKI K et al.: A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011; 219: 734-6.